Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ervogastat Formulations in Healthy Subjects
NCT03372044Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ervogastat in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Concentration and 3 more. Started Jan 2018; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03372044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372044.